CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Brecanavir, a protease inhibitor under investigation for HIV treatment, has been discontinued, according to its manufacturer. Glaxo Smith Kline said in a press release Monday that it will stop production of brecanavir, which was in Phase II of clinical development. Trial investigators have been notified and will move their patients to other antiretrovirals.
Senior vice president Lynn Marks of the GSK Medicine Development Center for Infectious Diseases said in the press release that the company is dedicated to continuing the fight against HIV. "Despite this disappointing outcome with brecanavir, we remain unwavering in our commitment to find new solutions to meet the challenges" of HIV and AIDS, Marks said. (The Advocate)
From our Sponsors
Most Popular
Watch Now: Advocate Channel
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Trending Stories & News
For more news and videos on advocatechannel.com, click here.